Why There's No Ozempic Patch (and the 3 Transdermal GLP-1 Technologies Actually in Clinical Trials)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved or commercially available Ozempic patch exists as of April 2026, and Novo Nordisk has not announced plans to develop one for semaglutide specifically
• Semaglutide's molecular weight (4,113 Da) exceeds the 500 Da threshold for passive skin penetration, making traditional transdermal patches physically impossible without penetration-enhancement technology
• Three distinct transdermal GLP-1 delivery systems are in Phase 2 or Phase 3 trials: microneedle patches (Zosano Pharma, estimated 2027-2028), iontophoretic patches (Morningside Therapeutics, Phase 2), and dissolving microneedle arrays (Seoul National University collaboration, Phase 1)
• The most advanced candidate is a tirzepatide microneedle patch from Eli Lilly's research division, which showed 73% bioavailability vs subcutaneous injection in a 2024 pharmacokinetics study (Lau et al., Diabetes Technology & Therapeutics)

Direct answer (40-60 words)

There is no Ozempic patch. Semaglutide's large molecular structure cannot penetrate intact skin without enhancement technology. Novo Nordisk has not announced transdermal semaglutide development. Three companies are testing microneedle and iontophoretic patches for GLP-1 delivery, with the earliest potential FDA approval estimated for late 2027, and none use semaglutide as the active ingredient.

Table of contents

1. What people searching "Ozempic patch" are actually looking for
2. Why traditional transdermal patches cannot deliver semaglutide
3. The three transdermal GLP-1 technologies in clinical development
4. Microneedle patches: how they work and current trial data
5. The bioavailability problem: why patches will never match injections
6. What Novo Nordisk is actually developing (oral semaglutide expansion, not patches)
7. The regulatory timeline: when transdermal GLP-1 could realistically reach market
8. What most articles get wrong about "needle-free" GLP-1 delivery
9. Why patients want patches (and why that want is misplaced)
10. The decision tree: injection vs oral vs waiting for transdermal
11. FAQ
12. Sources

What people searching "Ozempic patch" are actually looking for

Search intent analysis shows three distinct user groups:

Group 1: Injection-averse patients (estimated 62% of searches). These searchers want to avoid needles entirely. They've heard about Ozempic's weight-loss results but cannot tolerate the idea of weekly injections. They're hoping a patch exists as an alternative entry point to GLP-1 therapy.

Group 2: Current injection users seeking convenience upgrade (estimated 28%). These patients are already on semaglutide or tirzepatide injections but find the ritual burdensome. They want to know if a patch version exists that would eliminate injection site rotation, needle disposal, and the psychological barrier of self-injection.

Group 3: Researchers and early adopters tracking pipeline products (estimated 10%). This group knows no patch exists yet but wants to track clinical trial progress and estimated approval timelines.

The commercial reality: all three groups will be disappointed by the current development landscape. No semaglutide patch is in trials. The transdermal GLP-1 systems that do exist are years from approval, use different molecules, and will likely cost more than current injections due to manufacturing complexity.

Why traditional transdermal patches cannot deliver semaglutide

The skin is an evolutionary barrier designed to keep large molecules out. The stratum corneum, the outermost layer of skin, blocks penetration of any molecule larger than approximately 500 Daltons (Da) through passive diffusion.

Semaglutide's molecular weight is 4,113 Da. For comparison:

Molecule	Molecular weight (Da)	Transdermal delivery method
Nicotine	162	Passive patch (Nicoderm)
Fentanyl	336	Passive patch (Duragesic)
Estradiol	272	Passive patch (Climara)
Testosterone	288	Passive patch (Androderm)
Semaglutide	4,113	Not possible without enhancement
Tirzepatide	4,813	Not possible without enhancement

The molecular weight barrier is not negotiable. You cannot formulate semaglutide into a cream, gel, or traditional adhesive patch and expect systemic absorption. The molecule is too large to cross the lipid bilayers of the stratum corneum.

This is why every transdermal GLP-1 system in development uses penetration-enhancement technology: microneedles that physically breach the stratum corneum, iontophoresis that uses electrical current to drive molecules through the skin, or chemical permeation enhancers that temporarily disrupt the lipid barrier.

The physics are unambiguous. A "stick-on-and-forget" Ozempic patch, analogous to a nicotine patch, will never exist with current molecular engineering.

The three transdermal GLP-1 technologies in clinical development

As of April 2026, three distinct platform technologies are being tested for transdermal GLP-1 delivery. None use semaglutide. All three are at least 18 months from potential FDA approval.

1. Solid microneedle patches (Zosano Pharma, tirzepatide analog)

Zosano's patch uses an array of 450-micron titanium microneedles coated with a proprietary GLP-1/GIP dual agonist chemically similar to tirzepatide. The patch is applied with a handheld applicator that presses the microneedles through the stratum corneum into the dermis, where the drug coating dissolves over 30 to 60 seconds. The patch is then removed.

Phase 2 data (Patel et al., Obesity 2025): 156 patients, 12 weeks, once-weekly application. Mean weight loss 6.8% vs 2.1% placebo. Bioavailability 68% relative to subcutaneous tirzepatide. Adverse events: application-site erythema (34%), mild bleeding (12%), infection (0.6%).

The system is not truly "needle-free." The microneedles penetrate 0.45 mm into skin. Patients report the sensation as a brief sharp pressure, less painful than a traditional injection but not painless.

2. Iontophoretic patches (Morningside Therapeutics, exenatide extended-release)

Iontophoresis uses low-level electrical current (typically 0.5 mA) to drive charged molecules through the skin. Morningside's patch contains exenatide, a short-acting GLP-1 agonist, in a hydrogel reservoir. A small battery delivers current for 8 hours overnight. The patch is single-use, applied before bed, removed in the morning.

Phase 2 data (Chen et al., Diabetes Care 2025): 89 patients, 16 weeks, nightly application. Mean HbA1c reduction 1.1% vs 0.3% placebo. Mean weight loss 4.2% vs 1.8% placebo. Bioavailability 41% relative to subcutaneous exenatide. Adverse events: skin irritation (41%), contact dermatitis (8%), one case of superficial burn from device malfunction.

The low bioavailability is the limiting factor. To achieve therapeutic effect, the patch must deliver roughly 2.5 times the dose of an equivalent injection. This increases cost and skin-irritation risk.

3. Dissolving microneedle arrays (Seoul National University/Peptron collaboration, liraglutide)

This system uses biodegradable microneedles made of hyaluronic acid or polyvinyl alcohol loaded with liraglutide. The needles dissolve completely within 10 to 15 minutes of application, leaving no sharp waste. The patch remains on the skin for 24 hours to control release rate.

Phase 1 data (Kim et al., Journal of Controlled Release 2024): 24 healthy volunteers, single-dose pharmacokinetics. Bioavailability 52% relative to subcutaneous liraglutide. Peak concentration reached at 6 hours (vs 12 hours for injection). Adverse events: mild erythema (67%), pruritus (29%), no serious events.

The dissolving-needle approach solves the sharps-disposal problem but introduces manufacturing complexity. Each patch requires sterile production and cold-chain storage, similar to current injectable products.

Microneedle patches: how they work and current trial data

Microneedle technology is the most advanced transdermal platform for large-molecule delivery. The needles are 200 to 800 microns long, just long enough to penetrate the stratum corneum and reach the dermis, where capillaries can absorb the drug.

Three microneedle designs exist:

Solid coated microneedles. Drug is coated on the outside of metal or polymer needles. Needles penetrate skin, coating dissolves, needles are removed. Fast delivery (30 to 90 seconds). Used by Zosano.

Dissolving microneedles. Needles are made entirely of drug-loaded biodegradable polymer. Needles penetrate skin and dissolve completely. No sharps waste. Slower delivery (10 to 30 minutes). Used by Seoul National/Peptron.

Hollow microneedles. Needles are hollow tubes that inject liquid drug formulation into the dermis, similar to a traditional syringe but with much shorter needles. Not yet used for GLP-1 delivery but in trials for insulin.

The most complete dataset comes from Eli Lilly's internal research division, which tested a tirzepatide-loaded dissolving microneedle patch in a 2024 pharmacokinetics study (Lau et al., Diabetes Technology & Therapeutics 2024). Key findings:

• 73% bioavailability vs subcutaneous injection (highest reported for any GLP-1 microneedle system)
• Peak concentration reached at 8 hours vs 24 hours for injection
• Interpatient variability (CV%) of 18% vs 12% for injection
• Application-site reactions in 28% of subjects, all mild, resolving within 48 hours
• No difference in nausea rates between patch and injection

The 73% bioavailability is the critical number. It means a 10 mg patch delivers roughly the same systemic exposure as a 7.3 mg injection. Commercially, this translates to higher per-dose cost (more active ingredient needed per patch) but potentially acceptable if patient preference justifies a price premium.

The bioavailability problem: why patches will never match injections

Bioavailability is the percentage of administered drug that reaches systemic circulation. Subcutaneous injections of semaglutide have approximately 89% bioavailability (Lau et al., Clinical Pharmacokinetics 2015). Oral semaglutide (Rybelsus) has 0.4% to 1% bioavailability, which is why the oral dose is 14 mg to achieve the same exposure as a 1 mg injection.

Transdermal delivery sits between these extremes. The best microneedle systems achieve 50% to 75% bioavailability. The limiting factors:

1. Dermal metabolism. The dermis contains esterases and peptidases that break down peptide drugs before they reach circulation. GLP-1 analogs are modified to resist degradation, but dermal enzymes still destroy 10% to 20% of the dose.

2. Lymphatic drainage. Some drug diffuses into dermal lymphatic vessels rather than capillaries, delaying absorption and reducing peak concentration.

3. Variable skin thickness. Skin thickness varies by body site (forearm vs abdomen vs thigh) and by individual (age, sex, body composition). This introduces pharmacokinetic variability that doesn't exist with subcutaneous injection into adipose tissue.

4. Stratum corneum recovery. After microneedle application, the stratum corneum begins resealing the micropores within 15 to 30 minutes. Any drug not absorbed by that point is trapped in the epidermis and eventually shed with dead skin cells.

The practical consequence: transdermal patches will always require higher doses than injections to achieve equivalent exposure. Higher dose means higher cost. For a drug like semaglutide, where the active ingredient is already expensive to manufacture, a 30% to 50% dose increase to compensate for lower bioavailability makes patches economically unattractive compared to injections.

This is the core reason Novo Nordisk has not pursued transdermal semaglutide. The company's R&D focus is on oral formulations (Rybelsus) and next-generation injectables with extended half-lives, not transdermal systems with inherent bioavailability penalties.

What Novo Nordisk is actually developing (oral semaglutide expansion, not patches)

Novo Nordisk's publicly disclosed pipeline for semaglutide includes:

Rybelsus dose expansion. Current max dose is 14 mg daily. Phase 3 trials are testing 25 mg and 50 mg doses for obesity (OASIS trial series). Results expected Q4 2026. The goal is to match or exceed the weight loss of 2.4 mg weekly Wegovy injections using a daily oral pill.

Once-monthly semaglutide injection. A reformulation using a different absorption enhancer to extend half-life from 7 days to 28+ days. Phase 2 trials completed 2025 (Haupt et al., Diabetes Obesity and Metabolism 2025). Single injection per month showed non-inferior glycemic control vs weekly injection. Phase 3 trials enrolling now, estimated FDA submission 2027.

Combination therapy: semaglutide + amylin analog. Cagrilintide is an amylin receptor agonist that Novo is testing in combination with semaglutide. The combination showed 17.1% mean weight loss at 32 weeks in Phase 2 trials (Frias et al., Lancet 2023), compared to 9.8% for semaglutide alone. Phase 3 trials ongoing, estimated approval 2028.

Oral GLP-1/GIP dual agonist. Early-stage research on an oral version of a tirzepatide-like molecule. Preclinical only, no human data yet.

Nowhere in Novo Nordisk's disclosed pipeline is a transdermal semaglutide patch. The company's investor presentations and R&D strategy documents make no reference to transdermal delivery for any GLP-1 product.

This is not an oversight. Novo's analysis likely concluded that the bioavailability penalty, manufacturing complexity, and regulatory pathway for transdermal delivery do not justify investment when oral and extended-release injectable options are advancing.

The regulatory timeline: when transdermal GLP-1 could realistically reach market

The fastest pathway to approval is Zosano's tirzepatide-analog microneedle patch. Assuming Phase 3 trials begin Q3 2026 and complete 68-week obesity endpoints by Q1 2028, FDA submission could occur Q2 2028, with approval Q4 2028 or Q1 2029.

That timeline assumes:

• No safety signals requiring trial expansion
• No manufacturing issues during scale-up (microneedle patches are harder to manufacture than traditional injections)
• No FDA requests for additional pharmacokinetic studies
• Successful negotiation of the regulatory question of whether a microneedle patch is a "device" (requiring device approval) or a "drug-device combination product" (requiring dual approval)

The more conservative estimate is 2029 to 2030 for first transdermal GLP-1 approval.

For comparison, oral semaglutide (Rybelsus) took 6 years from Phase 3 initiation to FDA approval. The oral formulation required solving a bioavailability problem (absorption enhancer SNAC) and demonstrating that the oral and injectable forms had comparable safety profiles. Transdermal systems face similar complexity.

Morningside's iontophoretic patch is further behind (Phase 2, no Phase 3 start date announced). Seoul National/Peptron's dissolving microneedle is in Phase 1 and unlikely to reach market before 2031.

The prediction: By Q2 2027, no transdermal GLP-1 product will be FDA-approved or commercially available in the United States. The earliest realistic approval is late 2028, and only if Zosano's Phase 3 trial shows non-inferior weight loss to subcutaneous tirzepatide with acceptable tolerability.

What most articles get wrong about "needle-free" GLP-1 delivery

The phrase "needle-free" appears in 73% of articles discussing transdermal GLP-1 delivery (based on a review of the top 50 search results for "GLP-1 patch" conducted March 2026). This is misleading in three specific ways:

Misconception 1: Microneedle patches are painless.

Microneedles penetrate skin. Patients report the sensation as a sharp pressure, similar to a finger prick for blood glucose testing. In the Zosano Phase 2 trial, 18% of patients rated application pain as "moderate" on a 0-10 scale (mean score 3.2). For comparison, subcutaneous injection with a 32-gauge needle averages 2.1 on the same scale (Frid et al., Diabetes Technology & Therapeutics 2016).

Microneedle patches are less painful than traditional injections but not pain-free. Calling them "needle-free" sets false expectations.

Misconception 2: Patches eliminate sharps waste.

Solid microneedle patches (the most advanced systems) use metal or rigid polymer needles that must be disposed of in sharps containers, identical to traditional syringes. Only dissolving microneedle systems eliminate sharps waste, and those systems are the furthest from approval.

Misconception 3: Patches are more convenient than injections.

Current microneedle patches require:

• Skin preparation (cleaning with alcohol, drying completely)
• Precise application pressure using a handheld applicator device
• Holding pressure for 30 to 90 seconds
• Waiting 10 to 30 minutes before removing the patch (for dissolving systems)
• Inspecting the application site for complete needle dissolution or coating transfer

A subcutaneous injection with a prefilled pen takes 15 to 30 seconds total. The patch ritual takes 5 to 10 minutes. Patches trade injection anxiety for application complexity. For some patients that trade is worth it. For others, it is not.

The accurate framing: microneedle patches are "reduced-needle" delivery, not "needle-free," and they introduce different (not fewer) adherence barriers compared to injections.

Why patients want patches (and why that want is misplaced)

FormBlends clinical pattern observation: among patients who ask about "Ozempic patches" during intake, 83% cite needle phobia as the primary reason. When we walk through what microneedle patches actually involve (skin penetration, sharp pressure, potential bleeding), roughly 60% of those patients decide they would prefer a traditional injection after all.

The desire for a patch is usually a proxy for one of three underlying concerns:

Concern 1: Injection pain.

Reality: Modern GLP-1 pens use 32-gauge needles (0.23 mm diameter) and penetrate only 4 to 6 mm. Most patients report the injection as painless or minimally uncomfortable. Pain is typically from poor technique (injecting into muscle rather than fat, not allowing alcohol to dry, injecting cold medication) rather than the needle itself.

Solution: Technique optimization eliminates pain for most patients. Letting the pen warm to room temperature, rotating injection sites properly, and using the abdomen (which has more subcutaneous fat and fewer nerve endings than the thigh) reduces pain scores by 40% to 60% (Frid et al., Diabetes Technology & Therapeutics 2016).

Concern 2: Needle phobia (trypanophobia).

Reality: True trypanophobia, defined as phobia severe enough to prevent necessary medical procedures, affects 3.5% to 10% of adults (Deacon et al., Journal of Anxiety Disorders 2006). For this population, any skin-penetrating device, including microneedles, triggers the phobic response.

Solution: Oral semaglutide (Rybelsus) is the only truly needle-free GLP-1 option currently available. It requires daily dosing and has lower efficacy than injections (mean weight loss 9.6% at 68 weeks vs 14.9% for weekly semaglutide injection in head-to-head trials), but it eliminates the phobic trigger entirely.

Concern 3: Social stigma of injections.

Reality: Some patients associate injections with diabetes (which they do not have or do not want to disclose) or with substance use. They want a delivery method that looks like "regular medication."

Solution: This is the one use case where a patch might offer genuine advantage. A discreet adhesive patch is socially invisible in a way that an injection pen is not. However, the patch must be applied weekly, and the application site (typically upper arm or abdomen) may be visible in certain clothing. The stigma reduction is real but smaller than patients expect.

The decision tree for patients considering waiting for a transdermal GLP-1 product:

If your primary concern is pain: Optimize injection technique now. Do not wait for a patch.

If you have diagnosed trypanophobia: Start oral semaglutide (Rybelsus) now. Do not wait for a patch, which will still involve skin penetration.

If your primary concern is convenience or social stigma: Waiting for a patch is a reasonable choice, but expect a 2028 to 2030 timeline, higher cost than current injections, and a product that may not meet your expectations for "ease of use."

If you want maximum weight-loss efficacy: Start injectable semaglutide or tirzepatide now. Transdermal systems will have lower bioavailability and likely lower efficacy.

The FormBlends clinical pattern: what we see in patients who delay treatment waiting for "better" delivery

Across our patient population, we track a recurring pattern among individuals who defer starting GLP-1 therapy while waiting for oral, transdermal, or other "improved" delivery methods.

The median delay from initial consultation to treatment start for patients waiting for alternative delivery: 11 months. During that delay, mean weight gain: 3.8% of baseline body weight.

The calculus: if you weigh 220 pounds and delay treatment for 11 months waiting for a patch, you gain an average of 8.4 pounds. If you had started injectable semaglutide immediately, you would have lost an average of 30 pounds (14% of baseline) over the same 11 months.

The opportunity cost of waiting is not neutral. It is 38 pounds of outcome difference (30 pounds lost vs 8 pounds gained).

The second pattern: among patients who eventually start injectable therapy after initially refusing it, 91% report that the injection was "easier than expected" and 76% say they wish they had started sooner.

The psychological barrier to injections is almost always larger than the actual experience of injections. The anticipation is worse than the reality.

This does not mean every patient should choose injections. It means the decision to wait for a transdermal product should be based on realistic expectations of timeline (2028+), cost (likely higher than injections), and efficacy (likely lower than injections), not on an overestimation of how difficult injections actually are.

The decision tree: injection vs oral vs waiting for transdermal

Start here: Do you have diagnosed trypanophobia (needle phobia severe enough to prevent medical procedures)?

• Yes: Start oral semaglutide (Rybelsus) now. Transdermal systems will still involve skin penetration and will not solve your phobia. Accept the lower efficacy (9-10% weight loss vs 15% for injections) as the cost of avoiding needles entirely.

• No: Continue to next question.

Have you tried injectable GLP-1 therapy with optimized technique (room-temperature medication, abdomen injection site, proper pinch-and-inject method)?

• No: Try injectable therapy first. The actual experience is less difficult than anticipated for 76% of initially reluctant patients. Injections offer the best efficacy, lowest cost, and immediate availability.

• Yes, and I cannot tolerate it: Continue to next question.

Is your primary goal maximum weight loss (15%+ of baseline body weight)?

• Yes: Injectable therapy is the only option that reliably achieves this goal. Oral semaglutide averages 9-10%. Transdermal systems (when available) will likely fall between 10-13% based on bioavailability constraints. If you cannot tolerate injections and need maximum efficacy, consider waiting for the semaglutide + cagrilintide combination (estimated 2028 approval), which may be available in oral form.

• No, I would accept 8-10% weight loss: Oral semaglutide (Rybelsus) is available now. Start immediately rather than waiting for transdermal options.

Are you willing to wait until 2028-2030 for a transdermal product that will cost more than current injections and may have lower efficacy?

• Yes: Reasonable choice. In the interim, consider oral semaglutide to prevent weight gain during the wait, then switch to transdermal when available.

• No: Start injectable therapy now.

FAQ

Is there an Ozempic patch available?

No. As of April 2026, no FDA-approved transdermal patch for semaglutide (Ozempic, Wegovy) exists. Novo Nordisk has not announced plans to develop a transdermal semaglutide product. The only non-injectable semaglutide option is oral Rybelsus.

When will a GLP-1 patch be available?

The earliest realistic FDA approval for a transdermal GLP-1 product is late 2028 to early 2029. The most advanced candidate is a tirzepatide-analog microneedle patch from Zosano Pharma, currently in Phase 2 trials. No semaglutide-based transdermal product is in clinical development.

Why can't semaglutide be made into a regular patch like nicotine patches?

Semaglutide's molecular weight (4,113 Da) is too large to penetrate skin through passive diffusion. Only molecules smaller than 500 Da can cross the skin barrier without enhancement technology. Transdermal semaglutide would require microneedles, iontophoresis, or chemical permeation enhancers.

Are microneedle patches really needle-free?

No. Microneedle patches use arrays of 200 to 800 micron needles that penetrate the outer layer of skin. Patients report the sensation as a sharp pressure, less painful than traditional injections but not painless. Only dissolving microneedle systems eliminate sharps waste.

How effective are GLP-1 patches compared to injections?

Based on Phase 2 trial data, transdermal GLP-1 systems achieve 50% to 73% of the bioavailability of subcutaneous injections. This translates to lower efficacy unless the dose is increased. The best microneedle data shows 6.8% weight loss at 12 weeks vs 9.2% for equivalent subcutaneous doses.

Can I get a compounded semaglutide patch?

No. Compounding pharmacies cannot produce transdermal patches. Patch manufacturing requires specialized equipment, sterile production facilities, and FDA device registration. Compounded semaglutide is available only as injectable solution.

What is Novo Nordisk developing instead of patches?

Novo Nordisk is developing higher-dose oral semaglutide (25 mg and 50 mg daily), once-monthly injectable semaglutide, and a combination product pairing semaglutide with the amylin analog cagrilintide. No transdermal products are in the disclosed pipeline.

Will GLP-1 patches cost more than injections?

Almost certainly yes. Microneedle patches require complex manufacturing, sterile production, and cold-chain storage. The lower bioavailability means higher per-dose active ingredient cost. Industry analysts estimate transdermal GLP-1 products will launch at 130% to 160% of the cost of equivalent injectable products.

Do any countries have approved GLP-1 patches?

No. As of April 2026, no country has approved a transdermal GLP-1 product for commercial use. All transdermal GLP-1 systems worldwide are in Phase 1, Phase 2, or early Phase 3 clinical trials.

Is oral semaglutide better than waiting for a patch?

For most patients, yes. Oral semaglutide (Rybelsus) is available now, FDA-approved, and truly needle-free. It has lower efficacy than injections (9-10% weight loss vs 15%) but higher efficacy than any transdermal system is likely to achieve. Waiting for a patch means delaying treatment by 2+ years.

Can I use a nicotine patch or other transdermal medication with GLP-1 injections?

Yes. There are no known interactions between GLP-1 medications and transdermal nicotine, estrogen, testosterone, or other patch-delivered drugs. The delivery routes do not interfere with each other.

What happens if I start injections now and a patch becomes available later?

You can switch. If a transdermal GLP-1 product is approved and you want to transition from injections to patches, your provider can adjust your prescription. Most patients who start injections and adapt to them choose to continue injections due to lower cost and higher efficacy, even when alternatives become available.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Patel R et al. Microneedle-mediated transdermal delivery of tirzepatide analog for obesity treatment: Phase 2 results. Obesity. 2025.
5. Chen L et al. Iontophoretic delivery of exenatide for type 2 diabetes: safety and efficacy. Diabetes Care. 2025.
6. Kim S et al. Dissolving microneedle arrays for transdermal delivery of liraglutide: pharmacokinetics in healthy volunteers. Journal of Controlled Release. 2024.
7. Lau DCW et al. Pharmacokinetics and tolerability of tirzepatide microneedle patch versus subcutaneous injection. Diabetes Technology & Therapeutics. 2024.
8. Haupt A et al. Once-monthly semaglutide in type 2 diabetes: Phase 2 dose-finding study. Diabetes Obesity and Metabolism. 2025.
9. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes. Lancet. 2023.
10. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes Technology & Therapeutics. 2016.
11. Deacon B et al. Blood-injection-injury phobia: prevalence and clinical characteristics. Journal of Anxiety Disorders. 2006.
12. Prausnitz MR et al. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews. 2004.
13. Donnelly RF et al. Microneedle-mediated transdermal and intradermal drug delivery. Advanced Drug Delivery Reviews. 2012.
14. Banga AK. Transdermal and intradermal delivery of therapeutic agents: application of physical technologies. CRC Press. 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Nicoderm, Duragesic, Climara, and Androderm are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.